A New HIV Vaccine Candidate Using Lumpy Skin Disease Virus
Author Information
Author(s): Shen Yen-Ju, Shephard Enid, Douglass Nicola, Johnston Nicolette, Adams Craig, Williamson Carolyn, Williamson Anna-Lise
Primary Institution: University of Cape Town
Hypothesis
Can Lumpy Skin Disease Virus (LSDV) serve as a safe and effective vaccine vector for HIV-1?
Conclusion
LSDV is non-pathogenic in immunocompromised mice and shows promise as an immunogenic vaccine vector for HIV.
Supporting Evidence
- LSDV was shown to be non-pathogenic in immunocompromised mice.
- The rLSDV-grttn vaccine induced high levels of HIV-specific immune responses.
- Prime-boost regimens using rLSDV-grttn were more effective than homologous boosting.
Takeaway
Researchers are testing a new vaccine for HIV that uses a virus that usually affects cattle, and it seems to be safe and effective in mice.
Methodology
The safety and immunogenicity of LSDV expressing HIV-1 proteins were tested in immunocompromised mice using various prime-boost vaccination regimens.
Limitations
The study was conducted in mice, and the applicability to humans remains to be established.
Participant Demographics
Immunocompromised mice (RAG and CD4 T cell knockout mice)
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website